Immune Checkpoint Inhibition in Classical Hodgkin Lymphoma: From Early Achievements towards New Perspectives

Immune checkpoint inhibition (ICI) became one of the major breakthroughs in cancer treatment over the past decade and entered into therapy within standard oncohematology practice. ICI has demonstrated impressive response rates as salvage therapy in relapsed/refractory (R/R) classical Hodgkin lymphom...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Oncol
Main Authors: De Goycoechea, Diego, Stalder, Gregoire, Martins, Filipe, Duchosal, Michel A.
Format: Artigo
Jezik:Inglês
Izdano: Hindawi 2019
Teme:
Review Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6530161/
https://ncbi.nlm.nih.gov/pubmed/31205470
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2019/9513701
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki